Overview
Kawasaki disease, also known as mucocutaneous lymph node syndrome, is an acute, febrile illness that is self-limited and that primarily involves the medium- and small-sized muscular arteries of the body especially the coronary arteries.
Signs and symptoms of Kawasaki disease include fever persisting ≥5 days, bilateral bulbar conjunctival injection without exudate, polymorphous skin rash, changes in lips (eg reddened, dry or cracked) and oral cavity (eg strawberry tongue, diffuse oral and pharyngeal hyperemia), changes in the extremities and in the perineum (eg erythema of palms or soles, indurative edema of hands or feet, desquamation of perineal skin and periungal regions of hands or feet), and acute nonsuppurative cervical lymphadenopathy (≥1 lymph node, unilateral, >15 mm in diameter).
In the absence of a specific diagnostic test or pathognomonic feature, clinical criteria have been established to assist physicians in diagnosing Kawasaki disease.
The goals of treatment in the acute phase are to rapidly reduce the inflammation in the coronary arteries, minimize the incidence and progression of coronary artery aneurysm, and prevent arterial thrombosis.
For further information regarding the management of Kawasaki Disease, please refer to Disease Algorithm for the Treatment Guideline.
Signs and symptoms of Kawasaki disease include fever persisting ≥5 days, bilateral bulbar conjunctival injection without exudate, polymorphous skin rash, changes in lips (eg reddened, dry or cracked) and oral cavity (eg strawberry tongue, diffuse oral and pharyngeal hyperemia), changes in the extremities and in the perineum (eg erythema of palms or soles, indurative edema of hands or feet, desquamation of perineal skin and periungal regions of hands or feet), and acute nonsuppurative cervical lymphadenopathy (≥1 lymph node, unilateral, >15 mm in diameter).
In the absence of a specific diagnostic test or pathognomonic feature, clinical criteria have been established to assist physicians in diagnosing Kawasaki disease.
The goals of treatment in the acute phase are to rapidly reduce the inflammation in the coronary arteries, minimize the incidence and progression of coronary artery aneurysm, and prevent arterial thrombosis.
For further information regarding the management of Kawasaki Disease, please refer to Disease Algorithm for the Treatment Guideline.
